RxDoctor Payments Data

Joseph Moore, MD

Interventional Cardiology · Bolivar, MONPI 1790719417

Payments from drug & device makers

$10,629in general payments, 2019–2025

Across 51 payments — averaging $208.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$9K
  • Boston Scientific$745
  • Abiomed$407
  • Abbott$188
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$100
  • E.r. Squibb & Sons, L.L.C.$50
  • plus $150 from 8 others

What the payments were for

  • Speaking & faculty fees$8,85083%
  • Travel & lodging$7177%
  • Food & beverage$1,06210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)8$8,989
Boston Scientific13$745
Abiomed8$407
Abbott5$188
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)5$100
E.r. Squibb & Sons, L.L.C.3$50
Pfizer2$32
ZOLL Circulation Inc1$25
Novartis1$19
Amgen1$19
Livanova USA, Inc.1$18
AbbVie1$14
G Medical Diagnostic Services, Inc.1$12
GE HealthCare1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,629 in reported general payments places this provider in the 40th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$133,075
Medicare patients
962
Services billed
1,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban251$227,767
EntrestoSacubitril/Valsartan46$42,810
JardianceEmpagliflozin35$39,807
XareltoRivaroxaban49$36,110
Repatha SureclickEvolocumab42$29,977
BrilintaTicagrelor21$13,389
Repatha SyringeEvolocumab13$9,158
FarxigaDapagliflozin Propanediol11$8,640
Ranolazine ErRanolazine77$5,005
Metoprolol Succinate550$4,978
Diltiazem 24hr Er (Cd)Diltiazem Hcl101$2,623
ClopidogrelClopidogrel Bisulfate297$2,555
Atorvastatin Calcium291$2,410
Losartan Potassium243$1,877
Flecainide Acetate41$1,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$227,767251 claims
NovartisEntresto$19$42,81046 claims
Johnson & JohnsonXarelto$8,989$36,11049 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Bolivar

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →